You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Menopausal hormone therapy after breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, June 2005
|
| DOI | 10.1186/bcr1272 |
| Pubmed ID | |
| Authors |
Graham A Colditz |
| Abstract |
The use of postmenopausal hormone therapy after breast cancer remains controversial. Evidence shows variation by study design, and even among three randomized controlled trials there is substantial heterogeneity of results. Two Swedish trials of comparable size show relative risks of recurrence of 3.3 and 0.82 on comparing women receiving postmenopausal hormone therapy with control women. The extent of use of tamoxifen and concomitant use of progestins in combination with estrogen, although raised as one possible explanation for this heterogeneity, are not supported by evidence from trials of high-dose progestins used after breast cancer. Caution is needed when considering the use of postmenopausal hormone therapy after breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 26% |
| Student > Bachelor | 4 | 15% |
| Student > Master | 4 | 15% |
| Student > Doctoral Student | 2 | 7% |
| Professor | 2 | 7% |
| Other | 3 | 11% |
| Unknown | 5 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 67% |
| Mathematics | 1 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 5 | 19% |